PI-88 in Hepatocellular Carcinoma After Hepatectomy

Cellxpert Biotechnology

Status and phase: Completed; Phase 2

Conditions: Carcinoma, Hepatocellular

Treatments: Drug: PI-88

Study type: Interventional

Funder types: Industry

Identifiers

NCT00247728

MG 002

PR88204 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.

Full description

Although early diagnosis and treatment improve survival, hepatocellular carcinoma (HCC) is rarely cured and recurs frequently after regional therapy or transplantation. Hepatic resection can improve 5-year recurrence-free survival by up to 25%. Micrometastases of HCC have been detected by molecular techniques in 88% of patients at the time of surgery, and probably cause postoperative recurrence. Efforts to reduce the risk of recurrence after a curative resection have been tried, including various regimens of adjuvant and neoadjuvant therapy.

In this study , an anti-angiogenic agent, PI-88, is being used as an adjuvant therapy for HCC patients after curative hepatic resection. The efficacy endpoints, including tumour non-recurrence rate, time to first recurrence and 1-year survival rate are being evaluated. Several risk factors associated with tumour recurrence are also being analysed.

Enrollment: 172 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients have voluntarily given written informed consent

• Age ≥ 18 years but ≤ 75 years

• Males or females

• Histological diagnosis of hepatocellular carcinoma

• Curative hepatectomy within the past 4-6 weeks

• ECOG performance status of 0 to 2

• Cardiac functional capacity ≤ to class II (New York Heart Association)

• Patients with adequate renal, hepatic, and haematopoietic function as defined by:

  • Serum creatinine ≤ 2.0 mg/dL
  • Total bilirubin < 2.5 mg/dL
  • Neutrophil count > 1.5 x 10^9/L
  • ALT < 5 x upper limit of normal (ULN)
  • White blood cell (WBC) count ≥ 3 x 10^9/L
  • Platelet count ≥ 80 x 10^9/L
  • Prothrombin time international normalized ratio (PT-INR) ≤ 1.3 (or PT-INR ≤ 1.4 but PT within normal range)
  • Activated partial thromboplastin time (APTT) < ULN

Exclusion criteria

• Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.
• Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease
• Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.
• Patients with any tumour metastasis.
• Patients with uncontrolled infection or serious infection within the past 4 weeks.
• Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.
• Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.
• Patients with acute or chronic gastrointestinal bleeding within the past 1 year.
• Patients with a history of drug abuse or psychiatric disorder.
• Patients with known HIV infection or AIDS-related illness.
• Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.
• Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.
• Women who are pregnant or breast-feeding.
• Women of child-bearing potential who are not using an adequate method of contraception.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

172 participants in 3 patient groups

Untreated Control

No Intervention group

Description:

Untreated control arm

160 mg PI-88/Day

Experimental group

Description:

PI-88 160 mg/day SC injection

Treatment:

Drug: PI-88

250 mg PI-88/Day

Experimental group

Description:

PI-88 250 mg/day SC injection

Treatment:

Drug: PI-88